VPS35

Across TCGA pan-cancer cohorts, VPS35 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VPS35 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher VPS35 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VPS35 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, ESCA, and ACC are the cancer types where VPS35 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.164	0.579	.025	16	view →
ESCA	DFS	Median	II,III,IV	0.176	0.525	.024	12	view →
ACC	DFS	Median	IV	0.010	0.383	<.001	9	view →
UCEC	DFS	Median	II,III,IV	0.918	0.440	.034	8	view →
BLCA	DFS	Median	All	0.227	0.627	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VPS35–BRCA (OS)

Open the BRCA breakdown →